Interleukin‐38 alleviates cardiac remodelling after myocardial infarction. Issue 1 (20th November 2019)

• Record Type: Journal Article
• Authors: Wei, Yuzhen; Lan, Yin; Zhong, Yucheng; Yu, Kunwu; Xu, Wenbin; Zhu, Ruirui; Sun, Haitao; Ding, Yan; Wang, Yue; Zeng, Qiutang
• Is Part Of: Journal of cellular and molecular medicine. Volume 24:Issue 1(2020)
• Page Start: 371
• Page End: 384
• Publication Date: 2019-11-20
• Subjects: cardiac remodelling -- inflammation -- interleukin‐38 -- myocardial infarction; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.14741
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Excessive immune‐mediated inflammatory reaction plays a deleterious role in ventricular remodelling after myocardial infarction (MI). Interleukin (IL)‐38 is a newly characterized cytokine of the IL‐1 family and has been reported to exert a protective effect in some autoimmune diseases. However, its role in cardiac remodelling post‐MI remains unknown. In this study, we found that the expression of IL‐38 was increased in infarcted heart after MI induced in C57BL/6 mice by permanent ligation of the left anterior descending artery. In addition, our data showed that ventricular remodelling after MI was significantly ameliorated after recombinant IL‐38 injection in mice. This amelioration was demonstrated by better cardiac function, restricted inflammatory response, attenuated myocardial injury and decreased myocardial fibrosis. Our results in vitro revealed that IL‐38 affects the phenotype of dendritic cells (DCs) and IL‐38 plus troponin I (TNI)‐treated tolerogenic DCs dampened adaptive immune response when co‐cultured with CD4 + T cells. In conclusion, IL‐38 plays a protective effect in ventricular remodelling post‐MI, one possibility by influencing DCs to attenuate inflammatory response. Therefore, targeting IL‐38 may hold a new therapeutic potential in treating MI.